What is the current Price Target for the Summit Therapeutics PLC Sponsored ADR stock?

The average Summit Therapeutics PLC Sponsored ADR target price is $31.62. This is 92.92% higher than the current stock price. The highest price target is 162.66%, the lowest is -32.21%. 15 Analysts have issued a price target Summit Therapeutics PLC Sponsored ADR 2027 .

How high will the Summit Therapeutics PLC Sponsored ADR stock rise?

No reliable answer can be given as to how high the Summit Therapeutics PLC Sponsored ADR stock will rise. The performance of stocks, including the Summit Therapeutics PLC Sponsored ADR stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Summit Therapeutics PLC Sponsored ADR stock today?

The performance of Summit Therapeutics PLC Sponsored ADR stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Summit Therapeutics PLC Sponsored ADR stock fall?

The decline in Summit Therapeutics PLC Sponsored ADR stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Summit Therapeutics PLC Sponsored ADR Forecast, price target & analysts

$16.39

5.88%

Nasdaq, Sep 29, 04:27 pm EDT. Closed.

ISIN

US86627R1023

Symbol

SMMT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Analysts Charts Ownership News Strategies

Summit Therapeutics PLC Sponsored ADR Target price 2026 - Analyst rating & recommendation

Summit Therapeutics PLC Sponsored ADR Classifications & Recommendation

Buy

67%

Hold

33%

Summit Therapeutics PLC Sponsored ADR Price Target

Target Price	$31.62
Price	$16.39
Potential	92.92% register free of charge
Number of Estimates	15

	15 Analysts have issued a price target Summit Therapeutics PLC Sponsored ADR 2027 . The average Summit Therapeutics PLC Sponsored ADR target price is $31.62. This is 92.92% register free of charge higher than the current stock price. The highest price target is $43.05 162.66% register free of charge , the lowest is $11.11 32.21% register free of charge .
	A rating was issued by 24 analysts: 16 Analysts recommend Summit Therapeutics PLC Sponsored ADR to buy, 8 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Summit Therapeutics PLC Sponsored ADR stock has an average upside potential 2027 of 92.92% register free of charge . Most analysts recommend the Summit Therapeutics PLC Sponsored ADR stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '25	2026 Estimates
P/E		negative
EV/Sales		3,321.12

20 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast for earnings per share. The average Summit Therapeutics PLC Sponsored ADR EPS is

unlock

. This is

unlock

than earnings per share in the financial year 2025. The highest EPS forecast is

unlock

, the lowest is

unlock

This results in the following potential growth metrics and future valuations:

2027	$-1.18 3.28% unlock
2028	$-0.74 37.29% unlock
2029	$0.01 101.35% unlock
2030	$1.11 11,000.00% unlock
2031	$1.94 74.77% unlock
2032	$3.14 61.86% unlock
2033	$2.60 17.20% unlock

Current
2026	-13.45 8.09% unlock
2027	-13.89 3.27% unlock
2028	-22.29 60.48% unlock
2029	2,634.20 11,917.86% unlock
2030	14.78 99.44% unlock
2031	8.44 42.90% unlock
2032	5.22 38.15% unlock
2033	6.30 20.69% unlock

Summit Therapeutics PLC Sponsored ADR...

Current Summit Therapeutics PLC Sponsored ADR Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
HC Wainwright & Co.	Locked ➜ Locked	Locked	Sep 23 2026
Jefferies	Locked ➜ Locked	Locked	Sep 09 2026
HC Wainwright & Co.	Locked ➜ Locked	Locked	Aug 26 2026
Bernstein	Locked ➜ Locked	Locked	Aug 25 2026
HC Wainwright & Co.	Locked ➜ Locked	Locked	Aug 18 2026
Leerink Partners	Locked ➜ Locked	Locked	Aug 12 2026
Guggenheim	Locked ➜ Locked	Locked	Jul 24 2026

Analyst Rating	Date
Locked HC Wainwright & Co.: Locked ➜ Locked	Sep 23 2026
Locked Jefferies: Locked ➜ Locked	Sep 09 2026
Locked HC Wainwright & Co.: Locked ➜ Locked	Aug 26 2026
Locked Bernstein: Locked ➜ Locked	Aug 25 2026
Locked HC Wainwright & Co.: Locked ➜ Locked	Aug 18 2026
Locked Leerink Partners: Locked ➜ Locked	Aug 12 2026
Locked Guggenheim: Locked ➜ Locked	Jul 24 2026

Discover more stocks with a high price target

NIO ADR 115.40%

Alibaba Group Holding Ltd 73.67%

Rheinmetall 69.93%

Tencent Holdings Ltd. 58.19%

Infineon 55.67%

Adyen 54.76%

BYD 51.64%

Uber Technologies 48.53%

TUI 47.22%

Siemens Energy 43.40%

Adidas 43.11%

Deutsche Telekom 41.02%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now